This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: The study from the Seattle Health Department by Dr Nolan and colleagues¹ that found no isoniazid-associated deaths in 11,141 patients receiving isoniazid preventive treatment creates hope that isoniazid can be used more aggressively to prevent tuberculosis. However, during the same period the Centers for Disease Control and Prevention (CDC) confirmed that 8 patients in New York taking isoniazid preventive treatment died of liver failure or required a liver transplant.² A survey of pediatric liver transplant services found that 10 children or adolescents receiving isoniazid preventive treatment had the same previously unreported adverse events during a 10-year period ending in 1997 (Catherine Chao, MD, oral communication, April 1999). Furthermore, either the CDC or I have been made aware of 7 additional cases, which results in a total of 25 putative cases. (John Jereb, MD, oral communication, April 1999). These contradictory reports raise the question "Why is isoniazid safe . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Hepatotoxicity Associated With Isoniazid Preventive Therapy: A 7-Year Survey From a Public Health Tuberculosis Clinic
Charles M. Nolan, Stefan V. Goldberg, and Susan E. Buskin
JAMA. 1999;281(11):1014-1018.
ABSTRACT | FULL TEXT